Concepedia

Publication | Open Access

Omadacycline for Community-Acquired Bacterial Pneumonia

215

Citations

17

References

2019

Year

Abstract

Omadacycline was noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults. (Funded by Paratek Pharmaceuticals; OPTIC ClinicalTrials.gov number, NCT02531438 .).

References

YearCitations

Page 1